Skip to main content
Caplight Logo









IconOVir Bio

IconOVir Bio

Private
New York City, New YorkHealthcare & Life Scienceshttps://iconovir.com/

Last Round

Debt

Jun 6, 2023

Total Funding Raised

$97.2M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

IconOVir Bio is a biotechnology company that develops advanced oncolytic virus therapies designed to improve cancer treatment through personalized approaches.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

oncolytic virussolid tumor therapycancer immunotherapybiotech startupclinical stage biotechdrug developmentviral vector therapytumor lysisbiopharmaclinical trialadenovirus therapybiotech pipelinecancer researchdrug licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

IconOVir Bio Comparables

Compare IconOVir Bio with similar companies based on industry and business-model similarity.

IconOVir Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Virogin Biotech
85%
EpicentRx
84%
Lokon Pharma
83%

IconOVir Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtJun 6, 2023
Series AJan 5, 2021

Key People

Founding team and executive leadership

Mark McCamish

President and CEO

Executive Team

John Huynh

Chief Technology Officer

Executive Team

IconOVir Bio Investors

Notable investors and investment history

IconOVir Bio investors
InvestorRounds
Two River GroupSeries A
GVSeries A
Vida VenturesSeries A
Bellco CapitalSeries A
Logos CapitalSeries A
Wellington ManagementSeries A
Nextech InvestSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors increased 45% MoM.

  • Feb 21, 2025

    Sold oncolytic virus asset for $4 million in stock.

IconOVir Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

IconOVir Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about IconOVir Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range8
Year Founded2018
Last FundingJun 6, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?